ATE520406T1 - Kristalline form des ibandronat-natriums - Google Patents

Kristalline form des ibandronat-natriums

Info

Publication number
ATE520406T1
ATE520406T1 AT08002626T AT08002626T ATE520406T1 AT E520406 T1 ATE520406 T1 AT E520406T1 AT 08002626 T AT08002626 T AT 08002626T AT 08002626 T AT08002626 T AT 08002626T AT E520406 T1 ATE520406 T1 AT E520406T1
Authority
AT
Austria
Prior art keywords
ibandronate sodium
crystalline form
ray
crystalline
sodium
Prior art date
Application number
AT08002626T
Other languages
German (de)
English (en)
Inventor
Revital Lifshitz-Liron
Thomas Bayer
Judith Aronhime
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE520406(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE520406T1 publication Critical patent/ATE520406T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Artificial Filaments (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Secondary Cells (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Battery Electrode And Active Subsutance (AREA)
AT08002626T 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums ATE520406T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60402604P 2004-08-23 2004-08-23
US69086705P 2005-06-16 2005-06-16

Publications (1)

Publication Number Publication Date
ATE520406T1 true ATE520406T1 (de) 2011-09-15

Family

ID=35968334

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08002626T ATE520406T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums
AT05791142T ATE495747T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05791142T ATE495747T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür

Country Status (12)

Country Link
US (1) US7563918B2 (enExample)
EP (2) EP1930011B1 (enExample)
JP (1) JP4559431B2 (enExample)
KR (2) KR20090120011A (enExample)
CN (1) CN101022812A (enExample)
AT (2) ATE520406T1 (enExample)
CA (1) CA2576659A1 (enExample)
DE (2) DE602005025977D1 (enExample)
ES (1) ES2358269T3 (enExample)
IL (1) IL181298A (enExample)
PT (2) PT1930011E (enExample)
WO (1) WO2006024024A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044822T2 (hu) 2003-09-12 2019-11-28 Amgen Inc Cinakalcet HCl gyors feloldódású készítménye
AU2006210008B2 (en) * 2005-02-01 2009-10-08 F. Hoffmann-La Roche Ag Ibandronate polymorph B
CA2594802C (en) * 2005-02-01 2012-11-27 Uwe Eiermann Ibandronate polymorph a
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
EP2046342A4 (en) * 2006-07-28 2011-05-04 Reddys Lab Ltd Dr CRYSTALLINE FORM WITH IBANDRONIC ACID AND PROCESS FOR PREPARING THE SAME
JP2009516004A (ja) * 2006-11-16 2009-04-16 テバ ファーマシューティカル インダストリーズ リミティド イバンドロン酸ナトリウムの結晶形態
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
MX2009010850A (es) 2007-04-11 2009-11-02 Hoffmann La Roche Sintesis de ibandronato en multiples etapas.
WO2008131160A1 (en) * 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
US20090042839A1 (en) * 2007-08-09 2009-02-12 Sharon Avhar-Maydan Crystalline forms of ibandronate sodium
WO2009053445A2 (en) * 2007-10-26 2009-04-30 Chemo Ibérica, S.A. Polymorphic forms of ibandronate sodium and processes for preparation thereof
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
US20090118239A1 (en) * 2007-11-05 2009-05-07 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
SG173619A1 (en) 2009-02-13 2011-09-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US9192316B2 (en) 2009-05-15 2015-11-24 Nox Medical Systems and methods using flexible capacitive electrodes for measuring biosignals
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
CA2833111C (en) 2010-06-25 2018-08-21 Kormakur Hlini Hermannsson Biometric belt connector
JP6121421B2 (ja) 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
WO2013179305A1 (en) * 2012-06-01 2013-12-05 Hetero Research Foundation Ibandronate sodium solid dispersion
WO2014170909A2 (en) 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
EP3065638B1 (en) 2013-11-06 2024-01-10 Nox Medical ehf. Method, apparatus, and system for measuring respiratory effort
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
EP3500155B1 (en) 2016-08-19 2024-10-02 Nox Medical Method, system, and computer program for measuring respiratory effort of a subject
EP3629893A1 (en) 2017-06-02 2020-04-08 Nox Medical ehf. Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study
EP3678543A1 (en) 2017-09-08 2020-07-15 Nox Medical System and method for non-invasively determining an internal component of respiratory effort

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2639721B2 (ja) 1988-12-27 1997-08-13 富士重工業株式会社 内燃機関の燃焼室
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
DE19637890A1 (de) * 1996-09-17 1998-03-19 Max Planck Gesellschaft Biphosphonat-Liposomen
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
CN1202828C (zh) * 1999-05-21 2005-05-25 诺瓦提斯公司 二膦酸在制备抑制或逆转血管发生的药物中的用途
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
ES2254410T3 (es) * 2000-05-05 2006-06-16 F. Hoffmann-La Roche Ag Composicion farmaceutica como gel para administracion subcutanea que comprende acidos bisfosfonicos o sus sales.
ES2247123T7 (es) * 2000-06-20 2013-03-01 Novartis Ag Método para administrar bisfosfonatos
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
MXPA02001219A (es) * 2001-02-01 2005-06-06 Riderway Corp Composicion farmaceutica liquida para el tratamiento de enfermedades oseas.
ITMI20020908A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
PT1880744E (pt) * 2002-05-10 2015-02-13 Hoffmann La Roche Ácidos bisfosfónicos para o tratamento e a prevenção da osteoporose
US20050287135A1 (en) * 2002-05-17 2005-12-29 Wyeth Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
PL212072B1 (pl) * 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
EP2206717B1 (en) * 2003-12-23 2013-03-27 Alchymars S.p.A. A process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
AU2006210008B2 (en) 2005-02-01 2009-10-08 F. Hoffmann-La Roche Ag Ibandronate polymorph B
CA2594802C (en) 2005-02-01 2012-11-27 Uwe Eiermann Ibandronate polymorph a
WO2007074475A2 (en) 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate

Also Published As

Publication number Publication date
CA2576659A1 (en) 2006-03-02
KR20090120011A (ko) 2009-11-23
US20070179119A1 (en) 2007-08-02
DE602005025977D1 (de) 2011-03-03
IL181298A0 (en) 2007-07-04
EP1930011A2 (en) 2008-06-11
PT1713489E (pt) 2011-03-03
EP1713489B1 (en) 2011-01-19
CN101022812A (zh) 2007-08-22
JP2007512237A (ja) 2007-05-17
EP1713489A2 (en) 2006-10-25
WO2006024024A3 (en) 2006-06-29
WO2006024024A2 (en) 2006-03-02
EP1930011B1 (en) 2011-08-17
KR20070043043A (ko) 2007-04-24
IL181298A (en) 2011-04-28
US7563918B2 (en) 2009-07-21
ATE495747T1 (de) 2011-02-15
JP4559431B2 (ja) 2010-10-06
PT1930011E (pt) 2011-09-16
EP1930011A3 (en) 2008-06-18
ES2358269T3 (es) 2011-05-09
DE202005021414U1 (de) 2008-03-20

Similar Documents

Publication Publication Date Title
ATE520406T1 (de) Kristalline form des ibandronat-natriums
MY151295A (en) Pyrimidyl indoline compound
JO2793B1 (en) The new crystalline form 5 of agomelatine, its preparation process and the pharmaceutical ingredients it contains
MY147211A (en) Novel dihydropseudoerythromycin derivatives
MY138941A (en) Aryl-pyridine derivatives
UA86595C2 (ru) Гамма-кристаллическая форма гидрохлорида ивабрадина, способ ее получения и фармацевтическая композиция, которая ее содержит
TW200738241A (en) Pyridazine derivatives
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
UA83718C2 (ru) Кристаллическая форма iv агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
JO3360B1 (ar) الشكل البلوري الجديد 3 للأغوميلاتين وعملية تحضيره والمكونات الصيدلانية التي تحتويه
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
HRP20041092B1 (hr) Novi farmaceutski pripravci flibanserina
GEP20125433B (en) α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
TW200616976A (en) Pyrimidine derivatives
HRP20110162A8 (hr) Spojevi koji sadrže amlodipin i bisoprolol
MY139704A (en) Naphthalene derivatives for use as histamine-3-receptor ligands
BRPI0519414A2 (pt) composiÇço oral, composiÇço em pasta ou gel, e, mÉtodos para inibir crescimento bacteriano na cavidade oral, e para manter saéde sistÊmica
TW200740764A (en) Pyrazolone derivatives
TW200800993A (en) Organic compounds
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
TW200637817A (en) 5-aminoindole derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties